

News Releases

All Years

Search

Go

[Advanced Search](#)

NOV 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences

OCT 4, 2022

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

OCT 3, 2022

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Show

5

 per page



<https://inhibrx.investorroom.com/news-releases?o=15>